Shawn Guertin Will Join Davida’s BOD Effective September 15

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

September 8, 2020

Shawn Guertin will join the Davida board of directors, effective Sept. 15.

Shaw Guertin joins the Board with nearly 35 years of health care experience.  Most recently, Mr. Guertin spent eight years at Aetna, Inc., where he served as executive vice president, chief financial officer and chief enterprise risk officer during a period of significant growth driven by acquisitions and expansion into government programs, leading to Aetna’s eventual merger into CVS Health. At Aetna, Mr. Guertin was a key member of the executive leadership team driving the overall strategic direction of the enterprise and leading the development of the financial strategy to help grow the company into a multifaceted, dynamic health care organization.

“We are thrilled to have Shawn’s deep health care and managed care experience as part of our Board to help us continue to develop and execute on our strategy to transform kidney care,” said Javier Rodriguez, CEO of DaVita Inc. “He adds to our deep bench of financial and operational strength.”

“The expertise Shawn has cultivated throughout his career and, most recently at Aetna and CVS Health, will help DaVita continue to grow and lead within the larger health care community,” said Pam Arway, independent chair of the DaVita Inc. Board of Directors.

Mr. Guertin started his career as an actuary for The Travelers, where he held a number of roles over 11 years, eventually becoming part of the leadership of its group health business that was acquired by UnitedHealthcare.  After working for UnitedHealthcare, Guertin joined Coventry Health Care, where he spent 12 years, including serving as chief actuary and chief financial officer.

“DaVita’s commitment to its patients, teammates, partners and to true transformation in health care was part of the inspiration to join this team,” said Mr. Guertin. “I am excited to share my perspectives on managed care, capital planning and strategic direction as DaVita executes on its innovative strategy.”

Mr. Guertin will serve on DaVita’s audit committee. He also holds a position on the TriNet Board of Directors.

With the addition of Mr. Guertin, the DaVita Board is comprised of ten highly qualified directors, with 40% racial/ethnic and 40% gender diversity.

spot_img

DON'T MISS

Related Articles